Cancer drug developer CG Oncology targets near $1 billion valuation in US IPO

(Reuters) – Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering.

(Reporting by Niket Nishant in Bengaluru; Editing by Savio D’Souza)